PURPOSE: Over 90% of pancreatic adenocarcinoma PC express oncogenic mutant KRAS that constitutively activates the Raf-MEK-MAPK pathway conferring resistance to both radiation and chemotherapy. MEK inhibitors have shown promising anti-tumor responses in recent preclinical and clinical studies, and are currently being tested in combination with radiation in clinical trials. Here, we have evaluated the radiosensitizing potential of a novel MEK1/2 inhibitor GSK1120212 (GSK212,or trametinib) and evaluated whether MEK1/2 inhibition alters DNA repair mechanisms in multiple PC cell lines. METHODS: Radiosensitization and DNA double-strand break (DSB) repair were evaluated by clonogenic assays, comet assay, nuclear foci formation (γH2AX, DNA-PK, 53BP1, BRCA1, and RAD51), and by functional GFP-reporter assays for homologous recombination (HR) and non-homologous end-joining (NHEJ). Expression and activation of DNA repair proteins were measured by immunoblotting. RESULTS: GSK212 blocked ERK1/2 activity and radiosensitized multiple KRAS mutant PC cell lines. Prolonged pre-treatment with GSK212 for 24-48 hours was required to observe significant radiosensitization. GSK212 treatment resulted in delayed resolution of DNA damage by comet assays and persistent γH2AX nuclear foci. GSK212 treatment also resulted in altered BRCA1, RAD51, DNA-PK, and 53BP1 nuclear foci appearance and resolution after radiation. Using functional reporters, GSK212 caused repression of both HR and NHEJ repair activity. Moreover, GSK212 suppressed the expression and activation of a number of DSB repair pathway intermediates including BRCA1, DNA-PK, RAD51, RRM2, and Chk-1. CONCLUSION: GSK212 confers radiosensitization to KRAS-driven PC cells by suppressing major DNA-DSB repair pathways. These data provide support for the combination of MEK1/2 inhibition and radiation in the treatment of PC.
PURPOSE: Over 90% of pancreatic adenocarcinoma PC express oncogenic mutant KRAS that constitutively activates the Raf-MEK-MAPK pathway conferring resistance to both radiation and chemotherapy. MEK inhibitors have shown promising anti-tumor responses in recent preclinical and clinical studies, and are currently being tested in combination with radiation in clinical trials. Here, we have evaluated the radiosensitizing potential of a novel MEK1/2 inhibitor GSK1120212 (GSK212,or trametinib) and evaluated whether MEK1/2 inhibition alters DNA repair mechanisms in multiple PC cell lines. METHODS: Radiosensitization and DNA double-strand break (DSB) repair were evaluated by clonogenic assays, comet assay, nuclear foci formation (γH2AX, DNA-PK, 53BP1, BRCA1, and RAD51), and by functional GFP-reporter assays for homologous recombination (HR) and non-homologous end-joining (NHEJ). Expression and activation of DNA repair proteins were measured by immunoblotting. RESULTS:GSK212 blocked ERK1/2 activity and radiosensitized multiple KRAS mutant PC cell lines. Prolonged pre-treatment with GSK212 for 24-48 hours was required to observe significant radiosensitization. GSK212 treatment resulted in delayed resolution of DNA damage by comet assays and persistent γH2AX nuclear foci. GSK212 treatment also resulted in altered BRCA1, RAD51, DNA-PK, and 53BP1 nuclear foci appearance and resolution after radiation. Using functional reporters, GSK212 caused repression of both HR and NHEJ repair activity. Moreover, GSK212 suppressed the expression and activation of a number of DSB repair pathway intermediates including BRCA1, DNA-PK, RAD51, RRM2, and Chk-1. CONCLUSION:GSK212 confers radiosensitization to KRAS-driven PC cells by suppressing major DNA-DSB repair pathways. These data provide support for the combination of MEK1/2 inhibition and radiation in the treatment of PC.
Authors: S Carter; K L Auer; D B Reardon; M Birrer; P B Fisher; K Valerie; R Schmidt-Ullrich; R Mikkelsen; P Dent Journal: Oncogene Date: 1998-05-28 Impact factor: 9.867
Authors: Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho Journal: Genes Dev Date: 2003-12-17 Impact factor: 11.361
Authors: Christina Wu; Terence M Williams; Evan Wuthrick; Ryan Robb; Amy Webb; Lai Wei; Wei Chen; Sameh Mikhail; Kristen K Ciombor; Dana B Cardin; Cynthia Timmers; Somashekar G Krishna; Mark Arnold; Alan Harzman; Sherif Abdel-Misih; Sameek Roychowdhury; Tanios Bekaii-Saab Journal: Clin Cancer Res Date: 2020-04-06 Impact factor: 12.531
Authors: Ryan Robb; Linlin Yang; Changxian Shen; Adam R Wolfe; Amy Webb; Xiaoli Zhang; Marall Vedaie; Motoyasu Saji; Sissy Jhiang; Matthew D Ringel; Terence M Williams Journal: Clin Cancer Res Date: 2019-05-16 Impact factor: 12.531
Authors: Thomas J George; Aaron J Franke; A Bapsi Chakravarthy; Prajnan Das; Arvind Dasari; Bassel F El-Rayes; Theodore S Hong; Timothy J Kinsella; Jerome C Landry; James J Lee; Arta M Monjazeb; Samuel A Jacobs; David Raben; Osama E Rahma; Terence M Williams; Christina Wu; C Norman Coleman; Bhadrasain Vikram; Mansoor M Ahmed Journal: Cancer Date: 2019-04-24 Impact factor: 6.860
Authors: Nail Fatkhutdinov; Katrin Sproesser; Clemens Krepler; Qin Liu; Patricia A Brafford; Meenhard Herlyn; Katherine M Aird; Rugang Zhang Journal: Mol Cancer Res Date: 2016-06-13 Impact factor: 5.852
Authors: Linlin Yang; Changxian Shen; Cory J Pettit; Tianyun Li; Andrew J Hu; Eric D Miller; Junran Zhang; Steven H Lin; Terence M Williams Journal: Clin Cancer Res Date: 2020-03-27 Impact factor: 12.531